Immuron CEO Presentation at Emerging Growth Conference

Immuron Limited (ASX: IMC; NASDAQ: IMRN) filed a Form 6-K announcing that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on May 7, 2026. The filing includes the presentation materials which provide an overview of the company's business and pipeline. Immuron is developing orally delivered targeted polyclonal antibodies for infectious diseases, with its lead product Travelan® for travelers' diarrhea prevention. The company is also developing IMM-529 for recurrent Clostridioides difficile infection (CDI), which has shown promising preclinical results with an 80% prevention rate in primary disease and 67% protection against recurrence. The presentation highlights Immuron's platform technology using hyperimmune bovine colostrum to produce antibodies that can withstand the gastrointestinal environment. The company also has distribution rights for ProIBS® in Australia and New Zealand for irritable bowel syndrome treatment.